Incyte Q4 Adj EPS Misses Estimates, But Revenues Top
(RTTNews) - Incyte Corp. (INCY) on Tuesday reported net income of $201.10 million or $0.89 per share for the fourth quarter, sharply higher than $28.46 million or $0.13 per share in the prior-year quarter.
Excluding items, adjusted net income for the quarter was $1.06 per share, compared to $0.62 per share in the year-ago quarter.
Total revenues for the quarter rose 9 percent to $1.01 billion from $926.70 million in the same quarter last year.
On average, analysts polled by Thomson Reuters expected the company to report earnings of $1.16 per share on revenues of $1.0 billion for the quarter. Analysts' estimates typically exclude special items.
Looking ahead to fiscal 2024, Incyte now projects Jakafi net product revenue in a range of $2.69 billion to $2.75 billion. Other Hematology/Oncology net product revenues are projected between $325 million and $360 million.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
Incyte Says FDA Issued CRL For Ruxolitinib Extended-release Tablets
Incyte Q1 Results Top Estimates
DAX Moves In Tight Range; Earnings, Fed Policy Announcement In Focus
Pound Slides Against Majors
European Shares Mixed Ahead Of Fed Verdict
Asian Shares Rise Ahead Of Fed Decision
Aussie Rises As Robust Inflation Data Spurs RBA Rate Cut Pause
